Goodcell Unveils Personal Biobanking For Personalized Cell Therapies And Seamless Experience
As cellular therapies progress, GoodCell gives people the ability to keep their biology while also harnessing the power of their blood.
FREMONT, CA: "Our belief is that Personal Biobanking will impact the way preventative medicine is defined in the future. Being able to store and use stem cells for diagnostic purposes is only the beginning. GoodCell will inform members about their inherited and acquired genetics as well as track genetic changes over time. This knowledge, combined with access to their own biomaterial for personalized cellular therapies, can prevent or change the trajectory of certain diseases that impact our members." says Chris Garcia, GoodCell CEO.
Personal Biobanking is a proactive, preventative healthcare service that allows customers to deposit their own stem cells for future tailored therapy was unveiled by GoodCell, a life sciences business. Thousands of cell and gene therapies are being developed to treat diseases and conditions that affect every one out of every two adults in the United States. Ranging from neurodegenerative diseases like Alzheimer's and Parkinson's disease to breast and lung cancer to major chronic conditions like heart disease and diabetes.
David Scadden, Harvard Stem Cell Institute and GoodCell Co-founder, MD, says, "His terminal optimism about the future of personalized cellular therapeutics. Blood stem cells have been used for stem cell transplants to save lives for decades now. The stem cell represents a moment in which a new technology becomes available where you can envision it making a fundamental difference for the lives of people who have otherwise intractable diseases."
Quest Labs has collaborated with GoodCell to provide a seamless member experience. Members can arrange a blood draw at one of the 3,000+ Quest Labs nationwide once they receive their kit. The valuable blood components are removed safely and securely kept in GoodCell's state-of-the-art biorepository. After that, samples are delivered to GoodCell facilities for bioprocessing.
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance